. Rationale and Design of DUAL Study: Doxycycline to Upgrade response in light chain (AL) amyloidosis (DUAL): A phase 2 pilot study of a two-pronged approach of prolonged doxycycline with plasma cell-directed therapy in the treatment of AL amyloidosis. Contemporary Clinical Trials Communications 2017; 8:33-38
Date
04/25/2018
Author List
D’Souza A, Flynn K, Chhabra S, Dhakal B, Hamadani M, Jacobson K, Pasquini M, Weihrauch D, Hari P
Author
Anita D'Souza MD Professor in the Medicine department at Medical College of Wisconsin